PET studies in dementia

Annals of Nuclear Medicine

Volumn 17, Issue 2, 2003, Pages 79-89

  Herholz, Karl ^a  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

Acetylcholine; Alzheimer disease glucose metabolism; Automated image analysis; Dementia; Dopamine; Multicenter study; PET

Indexed keywords

ACETYLCHOLINESTERASE; FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; BASAL GANGLION; BRAIN METABOLISM; CEREBELLUM; CINGULATE GYRUS; COGNITION; COGNITIVE DEFECT; DEMENTIA; DOPAMINE METABOLISM; ENZYME ACTIVITY; FRONTAL CORTEX; GLUCOSE METABOLISM; HUMAN; LANGUAGE; LEWY BODY; NEOCORTEX; PARIETAL LOBE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SENSORIMOTOR CORTEX; TEMPORAL CORTEX; UNIVERSITY HOSPITAL; VISUAL CORTEX;

EID: 0037645793     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02988444     Document Type: Review

References (115)

1. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, Dekosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56 (9): 1133-1142.
2. Frackowiak RS, Magistretti PJ, Shulman RG, Altman JS, Adams M. Neuroenergetics: Relevance for functional brain imaging. Strasbourg: Human Frontier Science Program; 2001.
3. Sokoloff L. Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. [Review] J Cereb Blood Flow Metab 1981; 1 (1): 7-36.
4. Mata M, Fink DJ, Gainer H, Smith CB, Davidsen L, Savaki H, et al. Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J Neurochem 1980; 34 (1): 213-215.
5. Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci USA 1998; 95 (1): 316-321.
6. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, Di Chiro G. Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology 1983; 33 (8): 961-965.
7. Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Disease & Associated Disorders 1995; 9 (1): 6-16.
8. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, et al. Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET. Neuroimage 2002; 17: 302-316.
9. Zuendorf G, Kerrouche N, Herholz K, Baron JC. An efficient principal component analysis for multivariate 3D voxel-based mapping of brain functional imaging data sets as applied to FDG-PET and normal aging. Hum Brain Mapp 2003; 18: 13-21.
10. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Anti Neurol 1997; 42 (1): 85-94.
11. Gusnard DA, Raichle ME, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. Nat Rev Neurosci 2001; 2 (10): 685-694.
12. Burdette JH, Minoshima S, Vander Borght T, Tran, DD, Kuhl DE. Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology 1996; 198 (3): 837-843.
13. 18F]FDG PET: A clinical validation of statistical parametric mapping. Neuroimage 1999; 9 (1): 63-80.
14. Ishii K, Willoch F, Minoshima S, Drzezga A, Ficaro EP, Cross DJ, et al. Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med 2001; 42 (4): 548-557.
15. Salmon E, Collette F, Degueldre C, Lemaire C, Franck G. Voxel-based analysis of confounding effects of age and dementia severity on cerebral metabolism in Alzheimer's disease. Hum Brain Mapp 2000; 10 (1): 39-48.
16. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18 (4): 351-357.
17. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58 (12): 1985-1992.
18. McKhann G, Drachman D, Folstein MF, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Neurology 1984; 34: 939-944.
19. Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, et al. Metabolic impairment of association cortex predicts progression in Alzheimer's disease: a prospective multicenter positron emission tomography (PET) study. Eur J Neurol 1998; 5 (Suppl 3): S24.
20. Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001; 12 (4): 851-855.
21. Drzezga A, Lautenschlager N, Minoshima S, Spiegel S, Kurz A, Schwaiger M. Early identification of patients with Alzheimer's disease in a MCI group using F-18 FDG PET. J Cereb Blood Flow Metab 2001; 21 (Suppl): S426.
22. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98 (6): 3334-3339.
23. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334 (12): 752-758.
24. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-F-18-fluoro-2-deoxy-D-glucose positron-emission tomography (FDG PET). Proc NatlAcad Sci USA 2001; 98 (19): 10966-10971.
25. Yamaguchi S, Meguro K, Itoh M, Hayasaka C, Shimada M, Yamazaki H, et al. Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzheimer's disease as shown by MRI and PET. J Neurol Neurosurg Psychiatry 1997; 62 (6): 596-600.
26. Wilson RS, Barnes LL, Mendes de Leon CF, Aggarwal NT, Schneider JS, Bach J, et al. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology 2002; 59 (3): 364-370.
27. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156 (5): 675-682.
28. Hirono N, Mori E, Ishii K, Ikejiri Y, Imamura T, Shimomura T, et al. Frontal lobe hypometabolism and depression in Alzheimer's disease. Neurology 1998; 50 (2): 380-383.
29. Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord 1999; 10 (6): 494-504.
30. Kumar A, Newberg A, Alavi A, Berlin J, Smith R, Reivich M. Regional cerebral glucose metabolism in late-life depression and Alzheimer disease: a preliminary positron emission tomography study. Proc Natl Acad Sci USA 1993; 90 (15): 7019-7023.
31. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51 (6): 1546-1554.
32. Kertesz A, Munoz D. Pick's disease, frontotemporal dementia, and Pick complex: emerging concepts. Arch Neurol 1998; 55 (3): 302-304.
33. Lindau M, Almkvist O, Kushi J, Boone K, Johansson SE, Wahlund LO, et al. First symptoms - frontotemporal dementia versus Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11 (5): 286-293.
34. van Swieten JC, Stevens M, Rosso SM, Rizzu P, Joosse M, de Koning I, et al. Phenotypic variation in hereditary frontotemporal dementia with tau mutations. Ann Neurol 1999; 46 (4): 617-626.
35. Hosaka K, Ishii K, Sakamoto S, Mori T, Sasaki M, Hirono N, et al. Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration. J Neurol Sci 2002; 199 (1-2): 67-71.
36. Feany MB, Mattiace LA, Dickson DW. Neuropathologic overlap of progressive supranuclear palsy, Pick's disease and corticobasal degeneration. J Neuropathol Exp Neurol 1996; 55 (1): 53-67.
37. Karbe H, Grond M, Huber M, Herholz K, Kessler J, Heiss WD. Subcortical damage and cortical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography. J Neurol 1992; 239 (2): 98-102.
38. Soong B, Liu R, Wu L, Lu Y, Lee H. Metabolic characterization of spinocerebellar ataxia type 6. Arch Neurol 2001; 58 (2): 300-304.
39. Volkow ND, Hitzemann R, Wang GJ, Fowler JS, Wolf AP, Dewey SL, et al. Long-term frontal brain metabolic changes in cocaine abusers. Synapse 1992; 11 (3): 184-190.
40. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V. The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 1997; 337 (23): 1667-1674.
41. Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tinklenberg J, et al. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol 2000; 57 (2): 191-196.
42. Jellinger KA. The pathology of ischemic-vascular dementia: An update. J Neurol Sci 2002; 203-204: 153-157.
43. Ikeda M, Hokoishi K, Maki N, Nebu A, Tachibana N, Komori K, et al. Increased prevalence of vascular dementia in Japan: a community-based epidemiological study. Neurology 2001; 57 (5): 839-844.
44. Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Severity of vascular dementia is related to volume of metabolically impaired tissue. Arch Neurol 1992; 49 (9): 909-913.
45. Sultzer DL, Mahler ME, Cummings JL, Van Gorp WG, Hinkin CH, Brown C. Cortical abnormalities associated with subcortical lesions in vascular dementia. Clinical and position emission tomographic findings. Arch Neurol 1995; 52 (8): 773-780.
46. Johnson KA, Mueller ST, Walshe TM, English RJ, Holman BL. Cerebral perfusion imaging in Alzheimer's disease. Use of single photon emission computed tomography and iofetamine hydrochloride 1-123. Arch Neurol 1987; 44 (2): 165-168.
47. Powers WJ, Perlmutter JS, Videen TO, Herscovitch P, Griffeth LK, Royal HD, et al. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease. Neurology 1992; 42 (4): 765-770.
48. Frackowiak RS, Pozzilli C, Legg NJ, Du Boulay GH, Marshall J, Lenzi GL, et al. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 1981; 104 (Pt 4): 753-778.
49. Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimura J, Yonekura Y, et al. Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J Nucl Med 1994; 35 (1): 1-6.
50. Nagata K, Maruya H, Yuya H, Terashi H, Mito Y, Kato H, et al. Can PET data differentiate Alzheimer's disease from vascular dementia? Ann NY Acad Sci 2000; 903: 252-261.
51. Silverman DH, Small GW, Chang CY, Lu CS, Kung de Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001; 286 (17): 2120-2127.
52. Herholz K, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidhauer K, et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer disease. J Nucl Med 2002; 43 (1): 21-26.
53. Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, et al. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med 1994; 21 (10): 1052-1060.
54. Messa C, Perani D, Lucignani G, Zenorini A, Zito F, Rizzo G, et al. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: comparison with fluorine-18-FDG PET. J Nucl Med 1994; 35 (2): 210-216.
55. 18F] Fluoro-D-Glucose with Positron Emission Tomography into the Clinical Evaluation of Patients with Cognitive Impairment. Molecular Imaging & Biology 2002; 4 (4): 283-293.
56. Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, et al. Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease. Am J Psychiatry 2002; 159 (3): 474-476.
57. Huang C, Wahlund LO, Svensson L, Winblad B, Julin P. Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurol 2002; 2 (1): 9.
58. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001; 50 (3): 358-365.
59. Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 1998; 51 (1): 125-130.
60. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994; 14 (5): 783-801.
61. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology 1993; 43 (12 Suppl 6): S6-16.
62. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990; 95 (2): 119-139.
63. Verghese J, Crystal HA, Dickson DW, Lipton RB. Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999; 53 (9): 1974-1982.
64. Jellinger KA. Morphological substrates of mental dysfunction in Lewy body disease: an update. J Neural Transm Suppl 2000; 59 (1-2): 185-212.
65. Holthoff-Detto VA, Kessler J, Herholz K, Bönner H, Pietrzyk U, Würker M, et al. Functional effects of striatal dysfunction in Parkinson disease. Arch Neurol 1997; 54: 145-150.
66. Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[(18)F]fluolo-L-dopa PET study. Brain 2002; 125 (Pt 6): 1358-1365.
67. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with lewy bodies. Neurology 2000; 55 (10): 1575-1577.
68. Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O. Usefulness of a dopamine transporter PET ligand[(18)F]beta-CFT in assessing disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67 (6): 737-741.
69. Vander Borght TM, Kilbourn MR, Koeppe RA, DaSilva JN, Carey JE, Kuhl DE, et al. In vivo imaging of the brain vesicular monoamine transporter. J Nucl Med 1995; 36 (12): 2252-2260.
70. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217 (4558): 408-414.
71. Peny EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994; 5 (7): 747-749.
72. Candy JM, Perry RH, Perry EK, Irving D, Blessed G, Fairbairn AF, et al. Pathological changes in the nucleus basalis of Meynert in Alzheimer's and Parkinson's disease. J Neurol Sci 1983; 59: 277-289.
73. Mann DM, Yates PO, Marcyniuk B. The nucleus basalis of Meynert in multi-infarct (vascular) dementia. Acta Neuropathol (Berl) 1986; 71 (3-4): 332-337.
74. 11C]PMP) for in vivo measurements of acetylcholinesterase activity. Nucl Med Biol 1998; 25 (8): 751-754.
75. Namba H, Irie T Fukushi K, Iyo M. In vivo measurement of acetylcholinesterase activity in the brain with a radioactive acetylcholine analog. Brain Research 1994; 667 (2): 278-282.
76. Zündorf G, Herholz K, Lercher M, Wienhard K, Bauer B, Weisenbach S, Heiss W-D. PET functional parametric images of acetylcholine esterase activity without blood sampling. Senda M, Kimura Y, Herscovitch P, eds. Brain Imaging Using PET. San Diego, Ca.; Academic Press, 2002:41-46.
77. Herholz K, Lercher M, Wienhard K, Bauer B, Lenz O, Heiss W-D. PET measurement of cerebral acetylcholine esterase activity without blood sampling. Eur J Nucl Med 2001; 28: 472-477.
78. Shinotoh H, Namba H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A, et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol 2000; 48 (2): 194-200.
79. Herholz K, Bauer B, Wienhard K, Kracht L, Mielke R, Lenz O, et al. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism. J Neural Transm 2000;12:1457-1468.
80. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Disease & Associated Disorders 1993; 7 (2): 69-79.
81. Volkow ND, Ding YS, Fowler JS, Gatley SJ. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol Psychiatry, 2001; 49 (3): 211-220.
82. Sihver W, Langstrom B, Nordberg A. Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. Acta Neurol Scand Suppl 2000; 176: 27-33.
83. Bacskai BJ, Klunk WE, Mathis CA, Hyman BT. Imaging Amyloid-beta Deposits In Vivo. J Cereb Blood Flow Metab 2002; 22 (9): 1035-1041.
84. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002; 10 (1): 24-35.
85. Rapoport SI. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesisa critical review. Cerebrovascular & Brain Metabolism Reviews 1991; 3 (4): 297-335.
86. Imamura T, Ishii K, Hirono N, Hashimoto M, Tanimukai S, Kazui H, et al. Occipital glucose metabolism in dementia with lewy bodies with and without parkinsonism: a study using positron emission tomography. Dement Geriatr Cogn Disord 2001; 12 (3): 194-197.
87. Higuchi M, Tashiro M, Arai H, Okamura N, Hara S, Higuchi S, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000; 162 (2): 247-256.
88. Salmon E, Delbeuck X, Garraux G, Collette F, Herholz K, Kalbe E, et al. A predominant ventromedial frontopolar metabolic impairment demonstrated in frontotemporal dementia. J Neurol 2002; 249 (Suppl 1): 14.
89. Jauss M, Herholz K, Kracht L, Pantel J, Hartmann T, Jensen M, et al. Frontotemporal dementia: Clinical, neuroimaging, and molecular biological findings in 6 patients. European Archives of Psychiatry & Clinical Neuroscience 2001; 251: 225-231.
90. Ishii K, Sakamoto S, Sasaki M, Kitagaki H, Yamaji S, Hashimoto M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 1998; 39 (11): 1875-1878.
91. Friedland RP, Koss E, Lerner A, Hedera P, Ellis W, Dronkers N, et al. Functional imaging, the frontal lobes, and dementia. Dementia 1993; 4 (3-4): 192-203.
92. Hilker R, Voges J, Thiel A, Ghaemi M, Herholz K, Sturm V, et al. Deep brain stimulation of the subthalamic nucleus versus levodopa challenge in Parkinson's disease: measuring the on- and off-conditions with FDG-PET. J Neural Transmission 2002; 10: 1257-1264.
93. Berding G, Odin P, Brooks DJ, Nikkhah G, Matthies C, Peschel T, et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord 2001; 16 (6): 1014-1022.
94. Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. Brain 2001; 124 (Pt 8): 1601-1609.
95. Su PC, Ma Y, Fukuda M, Mentis MJ, Tseng HM, Yen RF, et al. Metabolic changes following subthalamotomy for advanced Parkinson's disease. Ann Neurol 2001; 50 (4): 514-520.
96. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 1999; 52 (3): 541-546.
97. 18F]fluorodopa positron emission tomographic studies. Movement Disorders 1990; 5 (3): 203-213.
98. Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 1993; 33 (5): 518-527.
99. Taniwaki T, Nakagawa M, Yamada T, Yoshida T, Ohyagi Y, Sasaki M, et al. Cerebral metabolic changes in early multiple system atrophy: a PET study. J Neurol Sci 2002; 200 (1-2): 79-84.
100. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002; 73 (5): 517-523.
101. 18F]fluorodeoxyglucose in multiple system atrophy and pule autonomic failure. Clinical Autonomic Research 1991; 1 (1): 27-36.
102. Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St Laurent RT. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol 1994; 36 (2): 166-175.
103. Perani D, Bressi S, Testa D, Grassi F, Cortelli P, Gentrini S, et al. Clinical/metabolic correlations in multiple system atrophy. A fludeoxyglucose F 18 positron emission tomographic study. Arch Neurol 1995; 52 (2): 179-185.
104. 18fluorodeoxyglucose positron emission tomography. Arch Neurol 2001; 58 (11): 1846-1851.
105. Blin J, Baron JC, Dubois B, Pillon B, Cambon H, Cambier J, et al. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 1990; 47 (7): 747-752.
106. Nagasawa H, Tanji H, Nomura H, Saito H, Itoyama Y, Kimura I, et al. PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration. J Neurol Sci 1996; 139 (2): 210-217.
107. Blin J, Vidailhet MJ, Pillon B, Dubois B, Feve JR, Agid Y. Corticobasal degeneration: decreased and asymmetrical glucose consumption as studied with PET. Movement Disorders 1992; 7 (4): 348-354.
108. Eidelberg D, Dhawan V, Moeller JR, Sidtis JJ, Ginos JZ, Strother SC, et al. The metabolic landscape of corticobasal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991; 54 (10): 856-862.
109. Gilman S, Junck L, Markel DS, Koeppe RA, Kluin KJ. Cerebral glucose hypermetabolism in Friedreich's ataxia detected with positron emission tomography. Ann Neurol 1990; 28 (6): 750-757.
110. Rudolf J, Grond M, Hilker R, Ghaemi M, Jacobs A, Heiss W. Relative sparing of the parietal cortex in cerebellar ataxia documented by positron emission tomography. Clinl Neurol Neurosurg 2000; 102 (4): 210-214.
111. Leenders KL, Frackowiak RS, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Movement Disorders 1986; 1 (1): 69-77.
112. Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 1986; 20 (3): 296-303.
113. Hayden MR, Martin WR, Stoessl AJ, Clark C, Hollenberg S, Adam MJ, et al. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 1986; 36 (7): 888-894.
114. Mazziotta JC. Huntington's disease: studies with structural imaging techniques and positron emission tomography. Semin Neurol 1989; 9 (4): 360-369.
115. Baxter LR Jr, Mazziotta JC, Pahl JJ, Grafton ST, St George-Hyslop P, Haines JL, et al. Psychiatric, genetic, and positron emission tomographic evaluation of persons at risk for Huntington's disease. Archives of General Psychiatry 1992; 49 (2): 148-154.